Unichem Labs unveils Loram trial results

Unichem Laboratories announced the results of its clinical trial with Loram, an anti-hypertensive combination of the company's two products Losartan and Ramipril, conducted at seven hospitals in India.

As per the first-ever clinical trial, the growing population of diabetes and hypertensive patients in India can reduce the chances of heart attack dramatically by controlling blood pressure effectively.

The kidneys of patients taking the durg can also be saved from being damaged. Loram is marketed by Unisearch- a division of Unichem.

LTM Medical Hospital, Leelavati Hospital from Mumbai, Banaras Hindu University from Banaras, K G Hospital (Coimbatore) S S K M Hospital from Kolkata and Chopda Medical and Research Centre from Nasik are among the hospitals which were part of the trials.

Single-drug therapy, according to the senior doctors involved with the trial, is known to control blood pressure in around 40 to 50 per cent of hypertensive population.

Many of these uncontrolled patients require combination therapy to control blood pressure effectively.

"Loram with its high safety profile and convenience of dose takes care of the needs of vast hypertensive population. Moreover, when hypertension is associated with diabetes, the risk of damage to kidneys and other organ is increased manifold. Thus, it is important to keep the blood pressure in diabetic hypertensives under stringent control," J Giri, director of KG Hospital, said.